Amicus Therapeutics, Inc. (0HF9.L)
USD 6.87
(0.81%)
USD 6.87
(0.81%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 399.35 Million USD | 21.3% |
| 2022 | 329.23 Million USD | 7.76% |
| 2021 | 305.51 Million USD | 17.11% |
| 2020 | 260.88 Million USD | 43.16% |
| 2019 | 182.23 Million USD | 99.72% |
| 2018 | 91.24 Million USD | 147.08% |
| 2017 | 36.93 Million USD | 644.86% |
| 2016 | 4.95 Million USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 1.22 Million USD | 237.19% |
| 2013 | 363 Thousand USD | -98.03% |
| 2012 | 18.41 Million USD | -14.1% |
| 2011 | 21.43 Million USD | 2224.73% |
| 2010 | 922 Thousand USD | -98.57% |
| 2009 | 64.35 Million USD | 330.0% |
| 2008 | 14.96 Million USD | 738.96% |
| 2007 | 1.78 Million USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 126.66 Million USD | 14.73% |
| 2024 Q1 | 110.4 Million USD | -4.07% |
| 2023 Q4 | 115.08 Million USD | 11.19% |
| 2023 Q1 | 86.27 Million USD | -2.07% |
| 2023 FY | 399.35 Million USD | 21.3% |
| 2023 Q2 | 94.5 Million USD | 9.54% |
| 2023 Q3 | 103.5 Million USD | 9.52% |
| 2022 Q4 | 88.09 Million USD | 7.84% |
| 2022 FY | 329.23 Million USD | 7.76% |
| 2022 Q1 | 78.71 Million USD | -4.19% |
| 2022 Q2 | 80.73 Million USD | 2.56% |
| 2022 Q3 | 81.69 Million USD | 1.19% |
| 2021 Q2 | 77.41 Million USD | 16.58% |
| 2021 Q4 | 82.15 Million USD | 3.28% |
| 2021 FY | 305.51 Million USD | 17.11% |
| 2021 Q1 | 66.4 Million USD | -5.91% |
| 2021 Q3 | 79.54 Million USD | 2.75% |
| 2020 Q3 | 67.43 Million USD | 8.15% |
| 2020 Q1 | 60.52 Million USD | 9.46% |
| 2020 Q2 | 62.35 Million USD | 3.02% |
| 2020 FY | 260.88 Million USD | 43.16% |
| 2020 Q4 | 70.57 Million USD | 4.65% |
| 2019 Q2 | 44.13 Million USD | 29.62% |
| 2019 Q4 | 55.29 Million USD | 13.38% |
| 2019 Q3 | 48.76 Million USD | 10.51% |
| 2019 Q1 | 34.04 Million USD | 4.29% |
| 2019 FY | 182.23 Million USD | 99.72% |
| 2018 Q2 | 21.3 Million USD | 27.63% |
| 2018 Q4 | 32.64 Million USD | 58.5% |
| 2018 FY | 91.24 Million USD | 147.08% |
| 2018 Q1 | 16.69 Million USD | 13.35% |
| 2018 Q3 | 20.59 Million USD | -3.35% |
| 2017 Q1 | 4.16 Million USD | 47.26% |
| 2017 FY | 36.93 Million USD | 644.86% |
| 2017 Q4 | 14.72 Million USD | 35.45% |
| 2017 Q3 | 10.87 Million USD | 51.91% |
| 2017 Q2 | 7.15 Million USD | 71.7% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | 4.95 Million USD | 0.0% |
| 2016 Q4 | 2.83 Million USD | 33.1% |
| 2016 Q3 | 2.12 Million USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 FY | - USD | -100.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 100.0% |
| 2014 Q2 | 475 Thousand USD | 4.17% |
| 2014 Q3 | 293 Thousand USD | -38.32% |
| 2014 Q1 | 456 Thousand USD | 40.74% |
| 2014 FY | 1.22 Million USD | 237.19% |
| 2014 Q4 | -1.22 Million USD | -517.75% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | 324 Thousand USD | 730.77% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | 39 Thousand USD | 0.0% |
| 2013 FY | 363 Thousand USD | -98.03% |
| 2012 Q2 | 10.63 Million USD | 36.83% |
| 2012 Q4 | - USD | -100.0% |
| 2012 Q3 | 5.79 Million USD | -45.49% |
| 2012 Q1 | 7.77 Million USD | 38.08% |
| 2012 FY | 18.41 Million USD | -14.1% |
| 2011 Q4 | 5.63 Million USD | -2.9% |
| 2011 Q3 | 5.79 Million USD | 43.51% |
| 2011 Q1 | 5.96 Million USD | 547.07% |
| 2011 Q2 | 4.04 Million USD | -32.28% |
| 2011 FY | 21.43 Million USD | 2224.73% |
| 2010 Q4 | 922 Thousand USD | 0.0% |
| 2010 FY | 922 Thousand USD | -98.57% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | -100.0% |
| 2009 FY | 64.35 Million USD | 330.0% |
| 2009 Q4 | 49.47 Million USD | 907.04% |
| 2009 Q3 | 4.91 Million USD | -8.36% |
| 2009 Q2 | 5.36 Million USD | 16.39% |
| 2009 Q1 | 4.6 Million USD | 6.01% |
| 2008 Q1 | 3.16 Million USD | 77.13% |
| 2008 FY | 14.96 Million USD | 738.96% |
| 2008 Q3 | 3.65 Million USD | -4.05% |
| 2008 Q2 | 3.8 Million USD | 20.47% |
| 2008 Q4 | 4.34 Million USD | 18.94% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q4 | 1.78 Million USD | 0.0% |
| 2007 FY | 1.78 Million USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| uniQure N.V. | 15.84 Million USD | -2420.709% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -11310.171% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -1177.98% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -1388.857% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -4558.299% |
| bluebird bio, Inc. | 29.49 Million USD | -1253.887% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -1804.597% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 232.28 Million USD | -71.926% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -214.345% |
| Illumina, Inc. | 4.5 Billion USD | 91.133% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 97.335% |
| Myriad Genetics, Inc. | 678.4 Million USD | 41.133% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 78.838% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 67.88% |
| Verastem, Inc. | - USD | -Infinity% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 95.954% |
| Biogen Inc. | 9.83 Billion USD | 95.94% |
| Nektar Therapeutics | 90.12 Million USD | -343.128% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Perrigo Company plc | 4.65 Billion USD | 91.422% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 6104.45% |
| Imunon, Inc. | - USD | -Infinity% |
| Geron Corporation | 237 Thousand USD | -168404.641% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -33487.553% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 99.068% |
| Editas Medicine, Inc. | 78.12 Million USD | -411.189% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -243.284% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 89.458% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 34.265% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.73% |
| Waters Corporation | 2.95 Billion USD | 86.492% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 83.492% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -126.608% |
| Evolus, Inc. | 202.08 Million USD | -97.618% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 96.955% |
| FibroGen, Inc. | 147.75 Million USD | -170.288% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 94.155% |
| OPKO Health, Inc. | 863.49 Million USD | 53.751% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 78.157% |
| Exelixis, Inc. | 1.83 Billion USD | 78.18% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -1000.912% |
| Zoetis Inc. | 8.54 Billion USD | 95.326% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -47.582% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 49.298% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 17.21% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 51.841% |
| Blueprint Medicines Corporation | 249.38 Million USD | -60.14% |
| Insmed Incorporated | 305.2 Million USD | -30.847% |
| TG Therapeutics, Inc. | 233.66 Million USD | -70.912% |
| Incyte Corporation | 3.69 Billion USD | 89.194% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 61.941% |